TBCRC 036 (UAB 1366): Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab + Pertuzumab, or Combination Trastuzumab + Lapatinib

Grant

Date/time Interval

  • January 8, 2014 - January 7, 2019
  • Total Award Amount

  • 38892.00
  • Direct Costs

  • 30867.00
  • Sponsor Award Id

  • Contributor

  • Nabell M.D., Lisle   Investigator  
  • Stringer-Reasor M.D., Erica   Investigator